Received Jun 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| CHIK | CHIKUNGUNYA (VIMKUNYA) | BAVARIAN NORDIC | 2 | Unknown | — |
The patient inadvertently received additional dose of Vimkunya; Case reference number US-BN-2026-000331 is a spontaneous case initially received from nurse via Bavarian Nordic (reference number: BN-2026-00034) on 24-Feb-2026 and concerns a male patient of unknown age. The patient's medical history and concomitant medication details were not provided. On 12-Sep-2025, the patient received the first dose of Vimkunya along with its constituent part: prefilled syringe (batch number: unknown), at an unknown dose, site or route of administration for an unknown indication. On 13-Feb-2026, after five months and on day, the patient received the second dose of Vimkunya along with its constituent part: prefilled syringe (batch number: unknown), at an unknown dose, site or route of administration (explicitly coded as 'extra dose administered'). At the time of the initial report, the patient did not experience any adverse effects due to the Vimkunya vaccine. No further information was provided.; Reporter's Comments: A male patient of unknown age received the second dose of Vimkunya for an unknown indication, which is considered as extra dose administered. The patient did not experience any adverse effects due to the Vimkunya vaccine. Extra dose administered is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Extra dose administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unknown age received the second dose of Vimkunya for an unknown indication, which is considered as extra dose administered. The patient did not experience any adverse effects due to the Vimkunya vaccine. Extra dose administered is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Extra dose administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.